Drugs / CYR-064
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06498687 | Apr 2025 → Jun 2026 | anosmia | University of Nebraska | Withdrawn | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06019000 | Sep 2023 → Nov 2025 | — | Cyrano Therapeutics, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | Cyrano Therapeutics, Inc. | Results Cyrano Therapeutics Announces Positive Topline Results from Phase 2 FLAVOR Trial of CYR-064, a Proprietary and Potential First-to-Market Regenerative Therapy for Persistent Smell Loss cyranotherapeutics.com ↗
CYR-064 also demonstrated durable improvements in smell function across multiple, prespecified, secondary efficacy endpoints. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-03 | Cyrano Therapeutics, Inc. | CYR-064 Phase 2 FLAVOR Trial Results to be Featured at the 72nd Annual Meeting of the American Rhinologic Society cyranotherapeutics.com ↗ |
| 2026-02-17 | Cyrano Therapeutics, Inc. | Cyrano Therapeutics Announces Positive Topline Results from Phase 2 FLAVOR Trial of CYR-064, a Proprietary and Potential First-to-Market Regenerative Therapy for Persistent Smell Loss cyranotherapeutics.com ↗ |
| 2025-04-29 | Cyrano Therapeutics, Inc. | Cyrano Therapeutics Completes Enrollment in Phase 2 FLAVOR Trial of CYR-064 for Post-Viral Smell Loss cyranotherapeutics.com ↗ |
| 2025-02-18 | Cyrano Therapeutics, Inc. | KYORIN and Cyrano Therapeutics Partner to Advance CYR-064 cyranotherapeutics.com ↗ |
| 2023-10-23 | Cyrano Therapeutics, Inc. | Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia) cyranotherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYR-064 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06019000 ↗ |
| Known as | theophylline | “This is a single-arm study that will investigate the use of intranasal theophylline (CYR-064) for the treatment of hyposmia and anosmia related to the onset of Parkinson's disease.” NCT06498687 ↗ |
| Route | Intranasal | “Treatment with nasal solution of CYR-064 twice a day for 24 weeks.” NCT06019000 ↗ |